ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
19.20
-0.27 (-1.39%)
At close: May 15, 2025, 4:00 PM
19.27
+0.07 (0.36%)
After-hours: May 15, 2025, 7:58 PM EDT
ADMA Biologics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for ADMA Biologics stock ranges from a low of $14 to a high of $32. The average analyst price target of $24.25 forecasts a 26.30% increase in the stock price over the next year.
Price Target: $24.25 (+26.30%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADMA Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Strong Buy Maintains $25 → $32 | Strong Buy | Maintains | $25 → $32 | +66.67% | May 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +30.21% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $26 | Strong Buy | Maintains | $18 → $26 | +35.42% | Nov 8, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +30.21% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | -6.25% | Oct 14, 2024 |
Financial Forecast
Revenue This Year
507.55M
from 426.45M
Increased by 19.02%
Revenue Next Year
649.39M
from 507.55M
Increased by 27.95%
EPS This Year
0.72
from 0.81
Decreased by -10.59%
EPS Next Year
1.01
from 0.72
Increased by 38.97%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 531.1M | 703.5M | 862.5M | ||
| Avg | 507.6M | 649.4M | 795.5M | ||
| Low | 480.3M | 592.6M | 720.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 24.5% | 38.6% | 32.8% | ||
| Avg | 19.0% | 27.9% | 22.5% | ||
| Low | 12.6% | 16.8% | 10.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.77 | 1.12 | 1.40 |
| Avg | 0.72 | 1.01 | 1.24 |
| Low | 0.68 | 0.91 | 1.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -5.4% | 55.1% | 38.8% |
| Avg | -10.6% | 39.0% | 23.3% |
| Low | -16.5% | 25.8% | 10.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.